| Literature DB >> 35599752 |
Sharifah Saffinas Syed Soffian1, Azmawati Mohammed Nawi1, Rozita Hod1, Mohd Rizal Abdul Manaf1, Huan-Keat Chan2, Muhammad Radzi Abu Hassan2.
Abstract
Regardless of the high global burden of colorectal cancer (CRC), the uptake of CRC screening varies across countries. This systematic review aimed to provide a picture of the disparities in recommendations for CRC screening in average-risk individuals using an ecobiosocial approach. It was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The literature search was conducted through Scopus, Web of Science, PubMed, and EBSCOHost. Full-text guidelines which were published between 2011 and 2021, along with guidelines which provided recommendations on CRC screening in average-risk individuals, were included in the review. However, guidelines focusing only on a single screening modality were excluded. Fourteen guidelines fulfilling the eligibility criteria were retained for the final review and analysis. Quality assessment of each guideline was performed using the AGREE II instrument. Disparities in guidelines identified in this review were classified into ecological (screening modalities and strategies), biological (recommended age, gender and ethnicities), and social (smoking history, socioeconomic status, and behavior) factors. In general, unstandardized practices in CRC screening for average-risk individuals are likely attributable to the inconsistent and non-specific recommendations in the literature. This review calls on stakeholders and policymakers to review the existing colorectal cancer screening practices and pursue standardization.Entities:
Keywords: biology; colorectal cancer; disparities; ecology; guidelines; screening; social
Year: 2022 PMID: 35599752 PMCID: PMC9115807 DOI: 10.2147/RMHP.S359450
Source DB: PubMed Journal: Risk Manag Healthc Policy ISSN: 1179-1594
Figure 1PRISMA flow diagram.
Keyword Search Used in the Identification Process
| Database | Search String |
|---|---|
| Scopus | TITLE-ABS-KEY ((“healthcare polic*” OR “health polic*” OR “health care polic*” OR “health guidelines” OR “guidelin*”) AND (“colorectal cancer*” OR “colorectal tumo*r*” OR “colorectal malignanc*” OR “colorectal neoplasia”) AND (“screening” OR “primary prevention” OR “early detection”)) |
| Web of Science | TS= ((“healthcare polic*” OR “health polic*” OR “health care polic*” OR “health guidelines” OR “guidelin*”) AND (“colorectal cancer*” OR “colorectal tumo*r*” OR “colorectal malignanc*” OR “colorectal neoplasia”) AND (“screening” OR “primary prevention” OR “early detection”)) |
| PubMed | ((“healthcare policy” OR “health policy” OR “health care policy” OR “health guidelines” OR “guidelines”) AND (“colorectal cancer*” OR “colorectal tumor*” OR “colorectal malignancy” OR “colorectal neoplasia”) AND (“screening” OR “primary prevention” OR “early detection”)) |
| EBSCOHost | ((“healthcare policy” OR “health policy” OR “health care policy” OR “health guidelines” OR “guidelines”) AND (“colorectal cancer*” OR “colorectal tumor*” OR “colorectal malignancy” OR “colorectal neoplasia”) AND (“screening” OR “primary prevention” OR “early detection”)) |
Scaled AGREE II Domain Scores for Each Guideline and Overall Assessment
| ACG | ACS 2018 | ACP 2019 | APWG 2015 | CTF 2016 | ESMO 2013 | Eu G 2013 | China 2014 | Saudi 2015 | Korea 2012 | NCCN 2020 | SEOM 2014 | USMSTF 2017 | USPSTF 2021 | Average Score (%) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope and Purpose (%) | 100 | 100 | 100 | 89 | 100 | 89 | 100 | 94 | 83 | 100 | 100 | 67 | 100 | 100 | 94 |
| Stakeholder Involvement (%) | 72 | 94 | 100 | 89 | 100 | 39 | 72 | 50 | 100 | 94 | 89 | 61 | 94 | 100 | 83 |
| Rigor of Development (%) | 90 | 98 | 96 | 92 | 96 | 52 | 100 | 48 | 92 | 100 | 90 | 58 | 94 | 100 | 86 |
| Clarity of Presentation (%) | 94 | 100 | 100 | 100 | 100 | 94 | 94 | 89 | 100 | 100 | 100 | 94 | 100 | 100 | 98 |
| Applicability (%) | 83 | 75 | 79 | 88 | 88 | 50 | 100 | 63 | 67 | 83 | 79 | 50 | 92 | 83 | 77 |
| Editorial Independence (%) | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 83 | 83 | 100 | 98 |
| Overall (out of 7) | 6 | 6 | 6 | 6 | 7 | 4 | 7 | 4 | 5 | 7 | 5 | 4 | 6 | 7 |
Characteristics of Included Guidelines
| Author, Year | Organization | Countries/Regions | Earliest Age at Screening | Age to Stop Screening | Primary Screening Modalities | Screening Interval | Screening Strategy | Additional Considerations |
|---|---|---|---|---|---|---|---|---|
| Shaukat et al., 2021 | American College of Gastroenterology (ACG) | United States | 50–75 years (strong recommendation) | Individualized screening beyond 75 years | Colonoscopy and FIT (strong recommendation) | FIT annually | Organized screening program (strong recommendation) | Outreach programs to boost screening among African Americans. |
| Wolf et al., 2018 | American Cancer Society (ACS) | United States | 50–75 years (strong recommendation) | Discourage individuals over age 85 years from continuing screening | FIT | Annually | NA | Emphasizes the importance of patient preferences and choice of screening options. |
| Qaseem et al., 2019 | American College of Physicians (ACP) | United States | 50–75 years | Discontinue CRC screening for those older than 75 years or adults with a life expectancy of 10 years or less | FIT or HSgFOBT | Every 2 years | NA | gFOBT benefit to reduce CRC mortality; harm of stool-based test is associated with subsequent colonoscopy. |
| Sung et al. 2015 | Asia Pacific Working Group | Asia Pacific region (14 Asia Pacific countries) | 50–75 years (grade B recommendation) | Discontinue screening at the age of more than 75 years | FIT (grade A recommendation) | Every 1–2 years | NA | Various ethnicity with different CRC risk. |
| Canadian Task Force on Preventive Health Care, 2016 | Canadian Task Force on Preventive Health Care | Canada | 50–59 years (weak recommendation) | Discourage screening for those age 75 years and above | FOBT (gFOBT or FIT) | Every 2 years | NA | Colonoscopy is not recommended as the primary screening test for CRC. |
| Labianca et al. 2013 | European Society for Medical Oncology (ESMO) | European Union member states | 50–74 years | Discontinue screening at 75 years and above | gFOBT | Annually or should not exceed 2 years | Organized screening | Clinical management and long-term implication of cancer survivorship. |
| Karsa et al. 2013 | European Colorectal Cancer Screening Guidelines Working Group | European Union member states | 60–64 years (grade B recommendation) | Discourage screening at 75 years and above | FOBT | Should not exceed 3 years | Organized screening | Average risk colonoscopy screening should not be performed before age 50 years. |
| Fang et al. 2014 | Chinese Society of Gastroenterology | China | 50–74 years | 75 years and above not included in the screening program | FOBT (at least two FOBT immunoassays) | Every 3 years | Opportunistic screening (direct colonoscopy or positive FOBT + colonoscopy) | Preliminary screening should be performed for risk stratification, followed by colonoscopy. |
| Lin JS et al. 2021 | US Preventive Services Task Force | United States | 50 years and above (strong consensus) | Individualized screening for age 76 to 85 years according to the overall health and screening history | Colonoscopy | Every 10 years | NA | Individuals underwent colonoscopy screening do not necessary perform additional FOBT screening. |
| Alsanea et al. 2015 | Tripartite Task Force from Saudi Society of Colon & Rectal Surgery, Saudi Gastroenterology Association and Saudi Oncology Society | Saudi | 45–70 years (strong recommendation) | Discourage screening for those age more than 70 years; consider individualized comorbidities and life expectancy | Colonoscopy | Every 10 years | NA | Colonoscopy alone every 10 years is the recommended modality. |
| Lee et al., 2012 | Korean Multi-Society Task Force | Korea | 50 years and older (strong recommendation) | Discontinue screening after age 80 years | FOBT | Annual | NA | Screening modalities recommended by the Korean guideline includes FOBT, CT colonography, double-contrast barium enema, and colonoscopy. |
| Provenzale et al. 2020 | National Comprehensive Cancer Network (NCCN) | United States | 50–75 years | Screening should be individualized for those aged 76–85 years based on comorbidity and life expectancy | Colonoscopy | Every 10 years | NA | Factors such as age, first-degree relatives with CRC, high BMI, cigarette smoking, diet, use of aspirin and adherence are important to consider for effective screening. |
| Segura PP et al 2014 | Spanish Society of Medical Oncology (SEOM) | Spain | 50–74 years | Individualized screening for those 75 years above | FIT | Every 1–2 years | Opportunistic screening | Combination strategy using stool test and flexible sigmoidoscopy should not be considered in CRC screening. |
| Rex et al 2017 | US Multi-Society Task Force on Colorectal Cancer (USMTF) | United States | 50–74 years | Discontinue screening at 75 years or having less than 10 years of life expectancy | Colonoscopy | Every 10 years | Organized screening | Sequential offers of screening test, multiple screening options and risk stratified screening are recommended. |
Abbreviations: FIT, fecal immunochemical test; gFOBT, guaiac-based fecal occult blood test; HSgFOBT, High-sensitivity guaiac-based fecal occult blood test; FOBT, fecal occult blood test; mt-sDNA, multitarget stool DNA; CTC, CT colonography; FS, flexible sigmoidoscopy.
Figure 2Summary of guidelines included based on countries and regions.
Comparison of CRC Screening Methods
| CRC Screening Test | Advantages | Disadvantages | Mechanism of Action | Target Population | Risk During Application | Specificity | Sensitivity |
|---|---|---|---|---|---|---|---|
| Stool test | Noninvasive | False positives may be due to peroxidase activity from high consumption of meat, fruit, vegetables and NSAIDs use. | It detects the peroxidase activity of hemoglobin in erythrocytes | Asymptomatic individuals | False positive when consumed high amount of red meat and vegetables containing heme iron | 95.2% | 52% |
| Stool test: | Noninvasive | Limited to detection of bleeding from the colon and rectum. | Utilizes specific monoclonal antibodies to Directly detects human globin within hemoglobin in the stool | Asymptomatic individuals | NA | 94% | 79% |
| Colonoscopy | Gold standard | High cost | Direct visualization during procedure enables removal of polyps or tumor cells identified in colon | If positive iFOBT result, colonoscopy is mandatory to enhance the screening effectiveness; symptomatic individuals | Bowel perforation, bleeding, deaths secondary to perforation | 94% | 91% |
| Flexible Sigmoidoscopy | Simpler bowel preparation compared to colonoscopy | Operator-dependent | Examine the distal 40 cm to 60 cm of the lower GI tract | Sigmoidoscopy can be performed once or 5-yearly in combination with iFOBT among the average risk individuals | Discomfort during procedure | 94% | 75% |
| CT colonography | Noninvasive assessment | Bowel preparation | Visualizes the structural assessment of colon and allows for identification of extracolonic findings | Asymptomatic individuals | Discomfort during procedure | NA | NA |
| Colon capsule endoscopy | Strict bowel preparation | Double-headed capsule is used to visualize the colon beyond the haustral folds | Patient is unwilling or unable to undergo colonoscopy | Capsule impaction and retention (1.4%), requiring surgical removal | 59% | 77% |